Research programme: adenosine receptor antagonists - Corvus/VernalisAlternative Names: Adenosine A2B receptor antagonist - Corvus/Vernalis; Immune checkpoint inhibitor B - Corvus/Vernalis; VER 4066; VER 4187; VER 6623; VER 6947; VER 7835
Latest Information Update: 15 Jan 2016
At a glance
- Originator Vernalis
- Developer Corvus Pharmaceuticals; Vernalis
- Class Purines; Pyrimidines; Thiophenes
- Mechanism of Action Adenosine A2 receptor antagonists; Adenosine A2B receptor antagonists; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
- Discontinued Anxiety disorders; Major depressive disorder